JP7750884B2 - ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 - Google Patents

ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法

Info

Publication number
JP7750884B2
JP7750884B2 JP2022578935A JP2022578935A JP7750884B2 JP 7750884 B2 JP7750884 B2 JP 7750884B2 JP 2022578935 A JP2022578935 A JP 2022578935A JP 2022578935 A JP2022578935 A JP 2022578935A JP 7750884 B2 JP7750884 B2 JP 7750884B2
Authority
JP
Japan
Prior art keywords
lenvatinib
hif
rcc
inhibitor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531675A (ja
JP2023531675A5 (https=
Inventor
ペリーニ，ロドルフォ・フルーリー
ピネイロ，エレイン・エム
ウィルマン・ロジェリオ，ジャクリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2023531675A publication Critical patent/JP2023531675A/ja
Publication of JP2023531675A5 publication Critical patent/JP2023531675A5/ja
Application granted granted Critical
Publication of JP7750884B2 publication Critical patent/JP7750884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022578935A 2020-06-22 2021-06-21 ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 Active JP7750884B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US63/042,307 2020-06-22
US202163146915P 2021-02-08 2021-02-08
US63/146,915 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (3)

Publication Number Publication Date
JP2023531675A JP2023531675A (ja) 2023-07-25
JP2023531675A5 JP2023531675A5 (https=) 2024-06-27
JP7750884B2 true JP7750884B2 (ja) 2025-10-07

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578935A Active JP7750884B2 (ja) 2020-06-22 2021-06-21 ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法

Country Status (10)

Country Link
US (1) US20230210838A1 (https=)
EP (1) EP4168008B1 (https=)
JP (1) JP7750884B2 (https=)
KR (1) KR20230026493A (https=)
CN (1) CN115803629A (https=)
AU (1) AU2021296151A1 (https=)
BR (1) BR112022026094A2 (https=)
CA (1) CA3183852A1 (https=)
MX (2) MX2022016406A (https=)
WO (1) WO2021262563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN119731864A (zh) 2023-02-28 2025-03-28 株式会社Lg新能源 电化学装置用分隔件和包括其的电化学装置
AU2024248799A1 (en) * 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eisai and Merck Receive Breakthrough Therapy Designation from FDA fo r LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as Combinat ion Therapy for Advanced and/or Metastatic Renal Cell Carcinoma, 2018年1 月9日, [retrieved on 2024. 8. 7], Retrieved from the Internet: <https:// www.merck.com/news/eisai-and-merck-receive-breakthrough-therapy-designat ion-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumabas-combination-therapy-for-advanced-and-or-metastatic-rena/>
The NEW ENGLAND JOURNAL of MEDICINE, 2021, Vol. 385, No. 22, pp. 203 6-2046

Also Published As

Publication number Publication date
EP4168008A1 (en) 2023-04-26
JP2023531675A (ja) 2023-07-25
MX2025014865A (es) 2026-01-07
US20230210838A1 (en) 2023-07-06
EP4168008B1 (en) 2026-03-18
MX2022016406A (es) 2023-01-30
CN115803629A (zh) 2023-03-14
CA3183852A1 (en) 2021-12-30
EP4168008A4 (en) 2024-08-07
WO2021262563A1 (en) 2021-12-30
AU2021296151A1 (en) 2023-02-02
BR112022026094A2 (pt) 2023-01-17
KR20230026493A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
JP7750884B2 (ja) ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
WO2018156812A1 (en) Treatment of egfr-driven cancer with fewer side effects
US20230181565A1 (en) Crenolanib combination therapy
CN115845070A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
Hedayat et al. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
AU2018380174A1 (en) Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2022551652A (ja) 線維芽細胞増殖因子受容体シグナル伝達の調節不全を伴う癌の標的処置
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP2023524789A (ja) Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ
JP2025156341A (ja) ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
Mehnert et al. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
JP7308145B2 (ja) 固形腫瘍を治療するための医薬組成物
HK40087480A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
JP2020510058A (ja) トリフルリジン／チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
US20210113692A1 (en) Dosing regimen
Bocci et al. Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data
WO2026037393A1 (zh) 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合
Massler et al. Enhancing the Anticancer Activity of Erlotinib in Glioblastoma
Tolcher et al. 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial
Kiyota 392 A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240619

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250925

R150 Certificate of patent or registration of utility model

Ref document number: 7750884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150